Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical rapamycin for facial fibrofolliculomas in Birt-Hogg-Dubé syndrome
NL-OMON35713Phase 3Active, not recruiting
- Sponsor
- Maastricht University
- Start
- Jan 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of sirolimus in Birt-Hogg-Dubé syndrome (BHDS) and Fibrofolliculoma (2 arms), sponsored by Maastricht University. Started Jan 2010; status: active, not recruiting.
02
Drugs
sirolimus
03
Conditions
Birt-Hogg-Dubé syndrome (BHDS)Fibrofolliculoma
Beyond the preview
Go deeper on NL-OMON35713.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON35713.